Synonyms: lichen sclerosus et atrophicus, balanitis xerotica obliterans, lichen albus, white spot disease, Csillag's disease, kraurosis vulvae
Lichen sclerosus (LS) is a chronic inflammatory dermatosis which usually affects the skin of the anogenital region in women, and the glans penis and foreskin in men (balanitis xerotica obliterans). It occurs less commonly in extragenital areas. It does not cause any systemic disease outside the skin.
The cause is unknown:
- There is some evidence for autoimmune mechanisms in the aetiology.
- There is an association with other autoimmune diseases.
- Borrelial infection may contribute - this is uncertain.
- One reported case was linked to treatment with imatinib mesylate.
The Royal College of Obstetricians and Gynaecologists states lichen sclerosus accounts for at least 25% of the women seen in dedicated vulval clinics. Dermatology clinics estimate one in 300 to one in 1,000 of all patients referred there have lichen sclerosus.
- Women: there are peaks of incidence in prepubertal girls and postmenopausal women.
- Men: incidence is lower in males; the incidence peaks in young boys and again in adults.
The lesions are white thickened patches (porcelain-white papules and plaques). These may progress to crinkled white patches (like cigarette paper). Active lesions may have areas of ecchymosis, hyperkeratosis or bullae.
Anogenital lichen sclerosus (LS)
- Itch - can be severe and disturb sleep.
- Pain can occur if there are fissures or erosions, leading to dyspareunia.
- Perianal lesions are common (about 30%) and may cause constipation.
- May be asymptomatic and found incidentally.
- White lesions as above. These may be patchy, or in a figure-of-eight area around the vulva and anus.
- Destructive scarring may cause shrinking of the labia, narrowing of the introitus, or the clitoris may be obscured by adhesions. The vagina is not affected.
- In girls, the signs may be mistaken for sexual abuse.
Lesions are usually on the prepuce, glans penis and coronal sulcus.
- Itching, soreness, haemorrhagic blisters.
- Dyspareunia, painful erections due to phimosis.
- If there is meatal scarring, poor urinary stream or dysuria.
- White patches on the glans or prepuce.
- Haemorrhagic vesicles or purpura.
- Rarely, blisters or ulcers.
- If scarring has occurred - phimosis, wasting of the prepuce, meatal narrowing/thickening.
- Perianal disease is rare.
- In boys, may present as phimosis. Perianal involvement rarely (if ever) occurs.
- May be asymptomatic.
- LS elsewhere is unusual; it is most often on the upper trunk, axillae, buttocks and lateral thighs.
- Oral lesions are extremely rare, but can affect sites where there is cornified stratified squamous epithelium, eg tongue, gingiva and hard palate. A case involving the tonsils was recently reported.
Diagnosis and investigation
- The diagnosis is usually made clinically.
- Is indicated only when there is diagnostic uncertainty or suspected malignancy.
- Is not always practical, eg in children - it may be preferable to start treatment and to monitor response.
- Is essential if lesions do not respond to adequate treatment.
- Skin swab to exclude infection, particularly if lesions are excoriated.
- Blood tests:
- Consider autoimmunity screen and TFTs if symptoms are present.
- In children, signs may mimic those of child sexual abuse. Note that a diagnosis of lichen sclerosus (LS) does not automatically exclude sexual abuse.
- Various other skin, genital or mucosal conditions, including:
Where should patients be treated and followed up?
- Lichen sclerosus (LS) can be managed by a GP, dermatologist or gynaecologist, depending on local expertise and protocols. Referral may be required to confirm the diagnosis.
- Specialist advice on treatment may be needed, eg if a woman does not appear to respond to treatment. Vulval clinics and urology clinics have a role, particularly if there are complications. The British Society of Dermatologists suggests follow-up visits at three and six months, to ensure response to treatment and that patients are confident managing their condition.
- Long-term follow-up is needed for patients with poorly controlled LS.
- Patients who respond well to treatment and need only small amounts of topical steroids, should be reviewed annually - this can be in primary care. Give patients clear instructions to report immediately any persistent new lumps, skin changes, erosions or ulcers.
Female anogenital LS
- The usual regimen is - once-daily (at night) use for one month, alternate nights for one month, then twice-weekly for one month with review at three months.
- If the patient's symptoms return during reduction of treatment, go back up to the frequency that was effective.
- A 30 g tube of clobetasol propionate should last 12 weeks; the patient is then reviewed.
- If the treatment has been successful, the hyperkeratosis, ecchymoses, fissuring and erosions should have resolved but the atrophy and colour change remain.
- Maintenance treatment may be required - either with less potent steroid preparations, or less frequent use of very potent steroids. For example, 30-60 g annually of clobetasol propionate is commonly required.
- Ointment bases are less allergenic, but the choice of base will depend on patient preference.
- For children, betamethasone dipropionate has been used successfully for vulval LS.
- Between 4 and 10% of women with anogenital LS will have steroid-resistant disease. The recommended second-line treatment is topical tacrolimus or pimecrolimus under the supervision of a specialist clinic.
NB: oestrogen or testosterone creams should not be used to treat LS. Testosterone is no better than petroleum jelly and there may be adverse effects. It must not be used in children.
Male anogenital LS
- Use potent topical steroids, eg clobetasol propionate or betamethasone valerate, applied once-daily until remission, then gradually reduced.
- May need intermittent use, eg once weekly, to maintain remission.
- Topical mometasone furoate has been used successfully in children with LS of the glans penis.
Other treatments for anogenital LS
- Treat any secondary infection.
- Advice to patients:
- Wash with bland emollients, eg aqueous cream; avoid topical irritants and tight clothing; use lubricants if necessary; give details of support groups.
- Warn patients to seek medical attention if there are possible signs of malignancy, ie if the area develops a persistent lump, change in texture of the skin (such as thickening) or a non-healing ulcer/erosion (see 'Complications and their treatment', below).
- If relevant, advise which creams/ointments may be used with condoms.
- If there is apparent treatment failure, consider:
- Compliance: for example, patients may be deterred by side-effect warnings on steroid preparations; elderly patients may have difficulty applying the creams.
- Is the diagnosis correct? There may be an additional problem, eg infection or allergy to the preparation.
- Is there a complication? (See 'Complications and their treatment', below.)
Shave excision and CO2 laser have been used successfully, treating symptoms and appearance. UVA-1 is the most successful phototherapy for LS.
Treatment is recommended if patients have features of active disease, eg ecchymosis, hyperkeratosis or progressive atrophy.
Complications and their treatment
- This is common and may cause urinary symptoms or sexual dysfunction.
- Renal failure due to obstructive uropathy has been reported.
- May require surgery, eg circumcision, meatal dilatation or vulval surgery.
- Constipation due to perianal fissures - prescribe softening laxatives.
- Squamous cell carcinoma (SCC):
- There is a small risk of SCC of the vulva (2-4% lifetime risk), and there may be an increased risk of SCC of the penis. Long-term follow-up is advisable.
- Warn patients about signs of malignancy and biopsy any suspicious lesions.
- Extragenital lesions do not appear to have any increased risk.
- Vulvodynia or penile dysaesthesia can occur following inflammatory conditions of the genitalia. This is a neuropathic type of pain. Treat with xylocaine ointment or amitriptyline.
- Sexual dysfunction:
- Be aware this may be a complication; offer referral.
- Some patients have complete remission after a course of treatment.
- In males, a course of steroids may prevent the need for circumcision.
- However, in some cases lichen sclerosus (LS) recurs. More complex cases may be an overlap syndrome with lichen planus, and may be more difficult to treat.
Further reading & references
- Goldstein AT, Thaci D, Luger T; Topical calcineurin inhibitors for the treatment of vulvar dermatoses. Eur J Obstet Gynecol Reprod Biol. 2009 Sep;146(1):22-9. Epub 2009 Jul 23.
- Skupsky H, Abuav R, High W, et al; Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia. J Cutan Pathol. 2009 Aug 23.
- The Management of Vulval Skin Disorders, Royal College of Obstetricians and Gynaecologists (February 2011)
- Guidelines for the management of lichen sclerosus, British Association of Dermatologists (2010)
- O'Connell TX, Nathan LS, Satmary WA, et al; Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008 Feb 1;77(3):321-6.
- Management of balanoposthitis, British Association for Sexual Health and HIV (2008)
- Dalziel K, Shaw S; Lichen sclerosus. BMJ. 2010 Feb 15;340:c731. doi: 10.1136/bmj.c731.
- Ajayi O, Stephens JC, Karim S, et al; Lichen sclerosis et atrophicus masquerading as tonsillar squamous cell carcinoma. J Laryngol Otol. 2009 Feb;123(2):e10. Epub 2008 Dec 23.
- Lichen sclerosus, DermNet NZ, updated September 2011
- Meffert J, Lichen Sclerosus et Atrophicus, Medscape, Mar 2011
- Christman MS, Chen JT, Holmes NM; Obstructive complications of lichen sclerosus. J Pediatr Urol. 2009 Jun;5(3):165-9. Epub 2009 Jan 30.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Hayley Willacy||Current Version: Dr Hayley Willacy||Peer Reviewer: Dr Hannah Gronow|
|Last Checked: 19/01/2012||Document ID: 2386 Version: 23||© EMIS|